![Matthew B. Francis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Matthew B. Francis
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Catena Biosciences, Inc.
![]() Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Direktor/Vorstandsmitglied | 17.11.2020 | - |
Technik-/Wissenschafts-/F&E-Leiter | 17.11.2020 | - | |
Gründer | 17.11.2020 | - |
Karriereverlauf von Matthew B. Francis
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sektoral
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Catena Biosciences, Inc.
![]() Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Commercial Services |
- Börse
- Insiders
- Matthew B. Francis
- Erfahrung